Top Page
Vaxart
(NASDAQ:VXRT)
Vaxart (VXRT) vs. SPDR S&P 500 ETF (SPY)
Vaxart Business Overview & Revenue Model
Vaxart Earnings Call Summary
Vaxart Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 47.40M | 28.70M | 7.38M | 107.00K | 892.00K | 4.05M | Gross Profit |
| 46.30M | 28.70M | 7.38M | -3.16M | -47.86M | -15.82M | EBIT |
| -57.16M | -66.29M | -83.35M | -114.59M | -72.75M | -30.17M | EBITDA |
| -45.73M | -54.87M | -72.13M | -103.12M | -66.45M | -28.26M | Net Income Common Stockholders |
| -58.12M | -66.95M | -82.47M | -107.76M | -70.47M | -32.22M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 41.94M | 51.72M | 39.71M | 93.72M | 166.49M | 126.87M | Total Assets |
| 158.56M | 166.39M | 91.83M | 153.85M | 221.17M | 152.58M | Total Debt |
| 16.83M | 17.53M | 20.09M | 21.70M | 13.01M | 7.21M | Net Debt |
| -11.87M | -7.70M | -14.67M | -22.31M | -130.74M | -119.66M | Total Liabilities |
| 112.94M | 107.46M | 34.02M | 43.25M | 33.64M | 29.18M | Stockholders Equity |
| 45.62M | 58.92M | 57.80M | 110.60M | 187.53M | 123.40M |
| Cash Flow | Free Cash Flow | ||||
| -33.73M | -45.32M | -72.32M | -104.38M | -64.99M | -24.97M | Operating Cash Flow |
| -33.17M | -44.76M | -70.45M | -94.78M | -59.83M | -23.75M | Investing Cash Flow |
| -3.07M | -21.32M | 43.95M | -20.41M | -49.10M | -1.22M | Financing Cash Flow |
| 38.20M | 56.56M | 15.24M | 17.46M | 125.80M | 138.31M |
Vaxart Technical Analysis
Vaxart Risk Analysis
Vaxart Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $86.43M | ― | -60.25% | ― | 255.31% | -141.39% | |
54 Neutral | $5.24B | 3.26 | -44.35% | 6.48% | 16.78% | -0.10% | |
53 Neutral | $140.18M | ― | -114.74% | ― | 433.43% | 49.04% | |
46 Neutral | $99.29M | ― | -59.45% | ― | ― | 48.92% | |
44 Neutral | $211.04M | ― | -34.72% | ― | -100.00% | -12.66% | |
40 Underperform | $114.55M | ― | -179.12% | ― | 30.23% | -21.32% | |
37 Underperform | $71.52M | ― | -246.26% | ― | ― | 51.02% |
Vaxart Corporate Events
On June 13, 2025, Vaxart held its reconvened 2025 annual meeting of stockholders, where two proposals were approved and two were rejected. Stockholders elected six directors and ratified the selection of WithumSmith+Brown, PC as the company’s independent accounting firm. However, they did not approve an amendment for a reverse stock split or the 2024 executive compensation plan. The company is evaluating its options following the rejection of the reverse stock split proposal and has canceled a special meeting previously scheduled for June 30, 2025.
The most recent analyst rating on (VXRT) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.
On June 11, 2025, Vaxart announced positive results from its Phase 1 clinical trial for its second-generation oral pill norovirus vaccine constructs. The trial demonstrated that the new constructs significantly increased antibody responses compared to the first-generation constructs, with a 141% and 94% increase in GI.1 and GII.4 norovirus blocking antibodies, respectively. The vaccines were well-tolerated with no serious adverse events reported. These results suggest the potential for improved protection against norovirus, a virus with no currently approved vaccine that causes millions of infections globally, leading to significant economic burdens. Vaxart plans to incorporate these findings into discussions with potential partners and aims to advance to a Phase 2b study, potentially starting in the latter half of 2025.
The most recent analyst rating on (VXRT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.
On June 2, 2025, Vaxart announced the adjournment of its 2025 annual meeting of stockholders to June 13, 2025, due to insufficient votes for a proposal to amend the company’s Restated Certificate of Incorporation for a reverse stock split. The company aims to provide additional time for stockholders to vote and solicit more support for the proposal, which is crucial for maintaining its Nasdaq listing. Leading proxy advisory firms ISS and Glass Lewis have endorsed the proposal, and Vaxart has engaged in discussions with major stockholders to address concerns, resulting in increased support.
The most recent analyst rating on (VXRT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.
On May 28, 2025, Vaxart, Inc. addressed additional frequently asked questions from retail investors regarding a proposed reverse stock split, which is to be voted on at their Annual Meeting on June 2, 2025. The company emphasized the importance of the reverse stock split to regain compliance with Nasdaq listing requirements, as failure to do so could result in delisting. Vaxart also highlighted its strategic decision to raise capital through a $40 million offering to extend its cash runway and advance its clinical programs, despite having an at-the-market offering in place. The company reassured investors that the reverse stock split would not inherently increase short selling or cause dilution and remains committed to exploring partnerships to support its vaccine development efforts.
The most recent analyst rating on (VXRT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.
On May 27, 2025, Vaxart announced the dosing of the first patient in a significant 10,000-participant Phase 2b clinical trial for its oral COVID-19 vaccine candidate. This trial aims to evaluate the vaccine’s efficacy, safety, and immunogenicity compared to an approved mRNA COVID-19 vaccine. The trial’s progression follows a positive safety review from an independent board, and it is supported by substantial funding from BARDA and NIAID under Project NextGen, highlighting the potential impact on Vaxart’s market positioning and contribution to next-generation COVID-19 vaccine development.
The most recent analyst rating on (VXRT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.
On May 21, 2025, Vaxart announced the adjournment of its 2025 annual meeting of stockholders to June 2, 2025, to allow additional time for stockholders to vote on proposals. The company’s board believes that approving a reverse stock split proposal is crucial for maintaining Nasdaq listing compliance and attracting investor interest. Stockholders who have already voted do not need to recast their votes, and proxies submitted will remain valid unless revoked.
The most recent analyst rating on (VXRT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.
On May 16, 2025, Vaxart announced that its board of directors approved resolutions to narrow the proposed reverse split range and reduce authorized shares at future stockholder meetings. The company urged stockholders to vote in favor of the reverse stock split proposal at the upcoming annual meeting to avoid Nasdaq delisting. Leading proxy advisory firms ISS and Glass Lewis support the proposal, which aims to maintain Vaxart’s Nasdaq listing, preserving stockholder liquidity and enabling investment from institutional investors.
The most recent analyst rating on (VXRT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.
On May 15, 2025, Vaxart, Inc. announced that it received approval from the Biomedical Advanced Research and Development Authority (BARDA) to begin dosing in the 10,000-participant portion of its Phase 2b clinical trial for its oral COVID-19 vaccine candidate. This trial, funded under Project NextGen, is a significant step in evaluating the efficacy and safety of Vaxart’s oral vaccine compared to existing mRNA vaccines, potentially impacting the company’s market positioning and offering a new approach to COVID-19 vaccination.
The most recent analyst rating on (VXRT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.
On May 12, 2025, Phillip Lee announced his resignation as Chief Financial Officer of Vaxart, Inc., effective upon the appointment of a successor. His resignation was not due to any disagreements with the company, and he will assist with the transition until June 1, 2025. On May 13, 2025, Vaxart appointed Jeroen Grasman as the new Chief Financial Officer, effective May 19, 2025. Grasman, who has over 20 years of experience in biotech financial leadership, previously served as CFO at AltruBio and held significant roles at PACT Pharma and Genentech. His appointment is expected to support Vaxart’s advancement of its oral vaccine programs.
The most recent analyst rating on (VXRT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.
On May 12, 2025, Vaxart, Inc. issued a press release addressing frequently asked questions about a proposed reverse stock split, which will be voted on at the company’s Annual Meeting on May 21, 2025. The reverse stock split is intended to help Vaxart regain compliance with Nasdaq’s minimum bid price requirement and avoid delisting. The proposal is supported by leading proxy advisory firms, and Vaxart’s board of directors recommends stockholders vote in favor of it. The reverse stock split is seen as a strategic move to maintain Nasdaq listing, potentially increase market visibility, and enhance long-term value, which is crucial for the company’s future growth and financing opportunities.
The most recent analyst rating on (VXRT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.
On May 5, 2025, Vaxart, Inc. announced significant progress in its vaccine programs, including the lifting of a government stop work order on April 24, 2025, which allows the continuation of a clinical trial for its COVID-19 vaccine candidate. The company is also advancing its norovirus program and is on track to report topline data by mid-2025. Vaxart is proposing a reverse stock split to be voted on at the upcoming annual meeting to avoid Nasdaq delisting, which could impact liquidity and funding opportunities. The company is implementing cost control measures to extend its cash runway into 2026 and is actively seeking non-dilutive funding to support its strategic initiatives.